<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="247">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01566682</url>
  </required_header>
  <id_info>
    <org_study_id>PL-208</org_study_id>
    <nct_id>NCT01566682</nct_id>
  </id_info>
  <brief_title>A Multi-Center Trial of the ProLung Test™</brief_title>
  <official_title>A Multi-Center Trial of the ProLung Test™ (Transthoracic Bioconductance Measurement) as an Adjunct to CT Chest Scans for the Risk Stratification of Patients With Pulmonary Lesions Suspicious for Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresh Medical Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huntsman Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Intermountain Health Care, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Greater Baltimore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tennessee Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fresh Medical Laboratories</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary Study hypothesis is that the ProLung Test will demonstrate safety and efficacy
      in the risk stratification of patients with pulmonary lesions identified by CT that are
      suspicious for lung cancer. A statistically significant result will indicate that patients
      with a high ProLung Test result have a greater risk of developing lung cancer than patients
      with a low test result.

      There are three Specific Aims of this study:

        1. Optimize and confirm the stability of the ProLung Test risk-stratification algorithm in
           patients with a diagnosis.

        2. Externally validate the efficacy of the ProLung Test risk-stratification algorithm by
           comparing the test result to the conclusive patient diagnosis.

        3. Assess the safety and tolerability of the ProLung Test procedures.

      Study Design This Study consists of two distinct phases, Stabilization and Validation. The
      Study will collect data from multiple sites (3 to 12), and each site may enroll patients and
      collect data for the Stabilization and Validation Phases with a minimum of three sites for
      the Validation Phase.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Clinical Efficacy in the risk stratification of patients with indeterminate lesions</measure>
    <time_frame>The ProLung Test will be performed within 60 days of a CT Scan that identifies a lung lesion suspicious for lung cancer and evaluated once a patient diagnosis is obtained.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Demonstrate safety and efficacy in the risk stratification of patients with pulmonary lesions identified by CT that are suspicious for lung cancer.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Solitary Pulmonary Nodule</condition>
  <condition>Multiple Pulmonary Nodules</condition>
  <arm_group>
    <arm_group_label>Indeterminate Pulmonary Lesions</arm_group_label>
    <description>Patients with Pulmonary Lesions as seen by CT</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with pulmonary lesions suspicious for lung cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects who meet all of the following criteria may be enrolled in this Study:

          1. Subject is male or female, age 18 or older.

          2. Subject has undergone CT scan of the lung(s) that indicates one or more nodules or
             lesions suspicious for lung cancer.

          3. Subject's pulmonary nodule or lesion is greater than 4mm. Size is determined by the
             largest nodule or lesion dimension identified from CT imaging.

          4. Subject meets one or more of the following conditions:

               -  indicated for a tissue biopsy of the lung

               -  indicated for surgical resection of the lung

               -  being followed by CT for nodule growth within a 1-year time frame*

                    -  subject must receive at least one follow-up CT by their 1-year enrollment
                       anniversary or within 60 days after their 1-year enrollment anniversary to
                       continue in the Study.

          5. Subject must be able to receive a ProLung Test

               -  within 60 days of abnormal CT (Inclusion Criterion 2 &amp; 3)

               -  within 60 days prior to the tissue biopsy or surgical resection (Inclusion
                  Criterion 4).

          6. Subject is capable of understanding and agreeing to fulfill the requirements of this
             Protocol.

          7. Subject has signed the IRB/IEC approved Informed Consent Form (&quot;ICF&quot;).

        Exclusion Criteria

        The following criteria will disqualify a subject from enrollment into this Study:

          1. Subject has an implanted electronic device in the chest.

          2. Subject receiving therapy for suspected chest infection such as fungal infection or
             tuberculosis.

          3. Subject with diagnosed malignancy other than lung cancer who has 2 or more suspicious
             pulmonary nodules.

          4. Subject has received an invasive medical or surgical procedure within the thoracic
             cavity within 30 days prior to the ProLung Test or within the previous 14 days for a
             bronchoscopic procedure.

          5. Subject presents with an anomalous physical or anatomical condition that precludes
             ProLung Test measurement.

          6. Subject will have undergone unusually strenuous exercise within 24 hours.

          7. Subject who has significant systemic diseases such as uncontrolled diabetes, advanced
             heart failure, or a recent myocardial infarction, or other medical condition such as
             severe morbid obesity that in the judgment of the Principal Investigator would make
             him/her unsuitable for the Study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fereidoun Abtin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Radiological Sciences Section of Thoracic Imaging</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chakravarthy Reddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huntsman Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Simoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael A Garff, BS, MBA</last_name>
    <phone>8012049625</phone>
    <email>mag@prolung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>LA</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Dermand</last_name>
      <phone>310-206-0396</phone>
      <email>jdermand@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Denise Aberle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fereidoun Abtin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Igor Barjaktarevic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Powers, RN, MSN, FNP</last_name>
      <phone>858-449-7218</phone>
      <email>atpowers@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura Peluso, RN</last_name>
      <phone>619-543-5840</phone>
      <email>lpeluso@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Samir Makani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center</name>
      <address>
        <city>Townson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Garnitha Ferguson</last_name>
      <phone>443-849-8058</phone>
      <email>gferfuso@gbmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Troy Gogoll</last_name>
      <phone>443-849-3592</phone>
      <email>Tgogoll@gbmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rex Yung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roel Almario, R.N., B.S.N.</last_name>
      <phone>313-916-3558</phone>
      <email>ralmari1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Michael Simoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Tian</last_name>
      <phone>713-745-2645</phone>
      <email>XTian@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Laila Noor</last_name>
      <phone>713-745-2645</phone>
      <email>LZNoor@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mardee Merrill</last_name>
      <phone>801-507-4608</phone>
      <email>mardee.merrill@imail.org</email>
    </contact>
    <investigator>
      <last_name>Denitza Blagev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>SLC</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natlie Graves</last_name>
      <phone>801-213-5672</phone>
      <email>natalie.graves@hci.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephen Bergquist</last_name>
      <phone>801-587-4284</phone>
      <email>stephen.bergquist@hci.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Chakravarthy Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 13, 2016</lastchanged_date>
  <firstreceived_date>March 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Lesion</keyword>
  <keyword>Lung Mass</keyword>
  <keyword>Lung Nodule</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Low-Dose CT</keyword>
  <keyword>CT</keyword>
  <keyword>Diagnostic</keyword>
  <keyword>Evaluation</keyword>
  <keyword>Bioconductance</keyword>
  <keyword>ProLung</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Pulmonary Nodules</mesh_term>
    <mesh_term>Solitary Pulmonary Nodule</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
